Cogent Biosciences, Inc. (COGT) key performance indicators and operating metrics (13 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Hazard ratio | 0.50 ratio | FY2025-Q4 |
| Total symptom score mean improvement | 65.00 percent | FY2025-Q1 |
| Peak enrollment | 413.00 | FY2025-Q1 |
| Pharmacodynamic inhibition | 90.00 percent | FY2024-Q4 |
| General and administrative non-cash stock compensation expense | 8.5M | FY2026-Q2 |
| Non-cash stock compensation expense in research and development expenses | 5M | FY2025-Q2 |
| Depreciation Expense operating income | -741K | FY2026-Q2 |
| Early Stage Preclinical And Discovery Programs operating income | -11.79M | FY2026-Q2 |
| Latestage Development operating income | -25.59M | FY2026-Q2 |
| Other Operational Infrastructure And Advisory Support operating income | -23.27M | FY2026-Q2 |
| Research And Development Personnel Related operating income | -17.6M | FY2026-Q2 |
| Research And Development Software Facilities And Other Strategic Support operating income | -6.54M | FY2026-Q2 |
| Stock- Based Compensation Expense operating income | -17.11M | FY2026-Q2 |
Back to COGT overview · COGT earnings · COGT holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.